Which Statement About Obesogen is Incorrect?,Which statement about obesogen is incorrect A. TBT is an organotin and is an agonist of PPARg. Thus, TBT can increase insulin sensitivity B. TZD is a class of synthetic PPARg agonists. Patients use TZD for type 2 diabetes treatment can also gain weight because PPARg agonists increase adipocyte differentiation C. Chemicals that affect central nervous system regulation of the body’s appetite could be obesogen D. Sex steroids play important role in the regulation of lipid accumulation. Chemicals that alter the sex steroid balance are potential obesogen E. PPARg agonists, such as TZD, can reduce inflammation to promote insulin sensitivity

Which Statement About Obesogen is Incorrect?

The statement that is incorrect is E. PPARg agonists, such as TZD, can reduce inflammation to promote insulin sensitivity. While PPARg agonists, such as TZD, are used to treat type 2 diabetes by increasing insulin sensitivity, there is no direct evidence that these agonists can reduce inflammation and promote insulin sensitivity (Kim et al., 2018; Yoon et al., 2020). Furthermore, PPARg agonists can also increase adipocyte differentiation, resulting in weight gain (O’Brien et al., 2016). Therefore, the statement that PPARg agonists can reduce inflammation to promote insulin sensitivity is incorrect. The Complexity of Obesogen: Exploring the Impact of Endocrine Disrupting Chemicals on Weight Gain and Insulin Sensitivity. Obesogen is the term used to describe endocrine-disrupting chemicals that can induce weight gain, obesity and related metabolic diseases. These environmental contaminants are found in many commonly used consumer products, including plastic, pesticides and personal care products. The chemicals can interfere with hormones and disrupt the body’s normal metabolism, resulting in weight gain and other endocrine-related health conditions. Cont…..